JP2016510797A - 大環状塩誘導性キナーゼ阻害剤 - Google Patents
大環状塩誘導性キナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2016510797A JP2016510797A JP2015562215A JP2015562215A JP2016510797A JP 2016510797 A JP2016510797 A JP 2016510797A JP 2015562215 A JP2015562215 A JP 2015562215A JP 2015562215 A JP2015562215 A JP 2015562215A JP 2016510797 A JP2016510797 A JP 2016510797A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- independently
- cycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C(C*1)CNCCCOc(cc[n]2nc3)nc2c3-c2cccc1c2 Chemical compound C(C*1)CNCCCOc(cc[n]2nc3)nc2c3-c2cccc1c2 0.000 description 2
- JHIPMFKEZKYARV-UHFFFAOYSA-N CC(c1cc(CO)cc(OCCNCCCN2)c1)=C=NN1C=CC2=NC1 Chemical compound CC(c1cc(CO)cc(OCCNCCCN2)c1)=C=NN1C=CC2=NC1 JHIPMFKEZKYARV-UHFFFAOYSA-N 0.000 description 2
- XOFAFAJYRYEGOA-UHFFFAOYSA-N CN(CCCO1)CCNc(cc[n]2nc3)nc2c3-c2cccc1c2 Chemical compound CN(CCCO1)CCNc(cc[n]2nc3)nc2c3-c2cccc1c2 XOFAFAJYRYEGOA-UHFFFAOYSA-N 0.000 description 2
- JLCHTQXFSKYXTA-UHFFFAOYSA-N Cc1cc(-c(cn[n]2cc3)c2nc3NCCCNCCO2)cc2c1 Chemical compound Cc1cc(-c(cn[n]2cc3)c2nc3NCCCNCCO2)cc2c1 JLCHTQXFSKYXTA-UHFFFAOYSA-N 0.000 description 2
- UGFKIOQOCWARQP-UHFFFAOYSA-N CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c(cc[n]1nc2)nc1c2-c1cc(NS(c2ccccc2[N+]([O-])=O)(=O)=O)cc(C(OC)=O)c1)CCO[Si](C)(C)C(C)(C)C)=O Chemical compound CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c(cc[n]1nc2)nc1c2-c1cc(NS(c2ccccc2[N+]([O-])=O)(=O)=O)cc(C(OC)=O)c1)CCO[Si](C)(C)C(C)(C)C)=O UGFKIOQOCWARQP-UHFFFAOYSA-N 0.000 description 1
- WJLKMOQVNDSIOY-UHFFFAOYSA-N CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c(cc[n]1nc2)nc1c2-c1cc([N+]([O-])=O)cc(C(OC)=O)c1)CCO)=O Chemical compound CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c(cc[n]1nc2)nc1c2-c1cc([N+]([O-])=O)cc(C(OC)=O)c1)CCO)=O WJLKMOQVNDSIOY-UHFFFAOYSA-N 0.000 description 1
- CONYUCOEYCEPDM-UHFFFAOYSA-N CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c1nc2c-3cn[n]2cc1)CCNc1cc-3cc(C(O)=O)c1)=O Chemical compound CC(C)(C)OC(N(CCCN(C(OC(C)(C)C)=O)c1nc2c-3cn[n]2cc1)CCNc1cc-3cc(C(O)=O)c1)=O CONYUCOEYCEPDM-UHFFFAOYSA-N 0.000 description 1
- WVUDYGOTGAPROH-UHFFFAOYSA-O CC(C)(C)[S+](C)OCCCNC(CSc(cc1)n[n]2c1ncc2-c1cc(NS(c2ccccc2[N+]([O-])=O)(=O)=O)ccc1)=O Chemical compound CC(C)(C)[S+](C)OCCCNC(CSc(cc1)n[n]2c1ncc2-c1cc(NS(c2ccccc2[N+]([O-])=O)(=O)=O)ccc1)=O WVUDYGOTGAPROH-UHFFFAOYSA-O 0.000 description 1
- SNJGFSGLLJXROI-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OCCN(CCNc1nc2c-3cn[n]2cc1)CCOc1cc-3cc(Cl)c1 Chemical compound CC(C)(C)[Si+](C)(C)OCCN(CCNc1nc2c-3cn[n]2cc1)CCOc1cc-3cc(Cl)c1 SNJGFSGLLJXROI-UHFFFAOYSA-N 0.000 description 1
- NUGYSFNZEVCCBR-UHFFFAOYSA-N CC1(CN=C2C=C3)N2N=C3SCCNCCCNc2cccc1c2 Chemical compound CC1(CN=C2C=C3)N2N=C3SCCNCCCNc2cccc1c2 NUGYSFNZEVCCBR-UHFFFAOYSA-N 0.000 description 1
- IBYNRLWZWFXVSP-ISVAMBKWSA-N CC1OCCNCCCOc(cc[n]2nc3)nc2c3/C(/C=C\C)=C1 Chemical compound CC1OCCNCCCOc(cc[n]2nc3)nc2c3/C(/C=C\C)=C1 IBYNRLWZWFXVSP-ISVAMBKWSA-N 0.000 description 1
- OZDVZLPKJGWGLU-UHFFFAOYSA-N CNCCN(CCNc1nc2c-3cn[n]2cc1)CCOc1cccc-3c1 Chemical compound CNCCN(CCNc1nc2c-3cn[n]2cc1)CCOc1cccc-3c1 OZDVZLPKJGWGLU-UHFFFAOYSA-N 0.000 description 1
- CXOLPMZNCPYTBQ-UHFFFAOYSA-N CNCCN(CCO1)CCOc(cc[n]2nc3)nc2c3-c2cccc1c2 Chemical compound CNCCN(CCO1)CCOc(cc[n]2nc3)nc2c3-c2cccc1c2 CXOLPMZNCPYTBQ-UHFFFAOYSA-N 0.000 description 1
- KMFYSIFQBOOMNO-UHFFFAOYSA-N COCc1cc(-c(cn[n]2cc3)c2nc3NCCN(CCO2)C3OC3C3CC3)cc2c1 Chemical compound COCc1cc(-c(cn[n]2cc3)c2nc3NCCN(CCO2)C3OC3C3CC3)cc2c1 KMFYSIFQBOOMNO-UHFFFAOYSA-N 0.000 description 1
- VHPIODSJYOQYNV-UHFFFAOYSA-N COCc1cc(-c(cn[n]2cc3)c2nc3NCCNCCO2)cc2c1 Chemical compound COCc1cc(-c(cn[n]2cc3)c2nc3NCCNCCO2)cc2c1 VHPIODSJYOQYNV-UHFFFAOYSA-N 0.000 description 1
- FWMCNVRIPHTYKG-LGMDPLHJSA-N COCc1cc(OCCC/C(/CCNC2=Nc3c-4cn[n]3CC2)=C/C(C2CC2)=O)cc-4c1 Chemical compound COCc1cc(OCCC/C(/CCNC2=Nc3c-4cn[n]3CC2)=C/C(C2CC2)=O)cc-4c1 FWMCNVRIPHTYKG-LGMDPLHJSA-N 0.000 description 1
- JLPPPQAIAYLJPQ-UHFFFAOYSA-N Fc1cc(OCCN(CCNc2nc3c-4cn[n]3cc2)C2CCNCC2)cc-4c1 Chemical compound Fc1cc(OCCN(CCNc2nc3c-4cn[n]3cc2)C2CCNCC2)cc-4c1 JLPPPQAIAYLJPQ-UHFFFAOYSA-N 0.000 description 1
- XAWTYXSUJFBYKZ-UHFFFAOYSA-N OCc1cc(OCCN(CC2CC2)CCNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound OCc1cc(OCCN(CC2CC2)CCNc2nc3c-4cn[n]3cc2)cc-4c1 XAWTYXSUJFBYKZ-UHFFFAOYSA-N 0.000 description 1
- YQNKAYSTXHWYOQ-UHFFFAOYSA-N OCc1cc(OCCNCCNc2nc3c-4cn[n]3cc2)cc-4c1 Chemical compound OCc1cc(OCCNCCNc2nc3c-4cn[n]3cc2)cc-4c1 YQNKAYSTXHWYOQ-UHFFFAOYSA-N 0.000 description 1
- KDJNMDAULAXAMK-UHFFFAOYSA-N [O-][N+](c(cccc1)c1S(N(CCCO)CCSc(cc[n]1nc2)nc1c2Br)(=O)=O)=O Chemical compound [O-][N+](c(cccc1)c1S(N(CCCO)CCSc(cc[n]1nc2)nc1c2Br)(=O)=O)=O KDJNMDAULAXAMK-UHFFFAOYSA-N 0.000 description 1
- JJSLZKATOABQIF-UHFFFAOYSA-N [O-][N+](c(cccc1)c1S(N(CCCOc(cc[n]1nc2)nc1c2-c1cc(O)ccc1)CCO)(=O)=O)=O Chemical compound [O-][N+](c(cccc1)c1S(N(CCCOc(cc[n]1nc2)nc1c2-c1cc(O)ccc1)CCO)(=O)=O)=O JJSLZKATOABQIF-UHFFFAOYSA-N 0.000 description 1
- OBQVTBZQPXGSLU-UHFFFAOYSA-N [O-][N+](c(cccc1)c1S(N(CCCOc1nc2c-3cn[n]2cc1)CCOc1cc-3ccc1)(=O)=O)=O Chemical compound [O-][N+](c(cccc1)c1S(N(CCCOc1nc2c-3cn[n]2cc1)CCOc1cc-3ccc1)(=O)=O)=O OBQVTBZQPXGSLU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2013/055389 | 2013-03-15 | ||
| EP2013055389 | 2013-03-15 | ||
| PCT/EP2014/055168 WO2014140313A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic salt-inducible kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510797A true JP2016510797A (ja) | 2016-04-11 |
| JP2016510797A5 JP2016510797A5 (enExample) | 2017-03-30 |
Family
ID=50588637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562215A Ceased JP2016510797A (ja) | 2013-03-15 | 2014-03-14 | 大環状塩誘導性キナーゼ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9586975B2 (enExample) |
| JP (1) | JP2016510797A (enExample) |
| KR (1) | KR20150133767A (enExample) |
| CN (1) | CN105209040A (enExample) |
| AU (1) | AU2014230125A1 (enExample) |
| BR (1) | BR112015022650A8 (enExample) |
| CA (1) | CA2906262A1 (enExample) |
| EA (1) | EA201591794A1 (enExample) |
| HK (1) | HK1219057A1 (enExample) |
| IL (1) | IL241325A0 (enExample) |
| MX (1) | MX2015012528A (enExample) |
| SG (1) | SG11201507493SA (enExample) |
| WO (1) | WO2014140313A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023516551A (ja) * | 2020-01-31 | 2023-04-20 | オンコデザイン エス．ア． | 大環状ｒｉｐ２－キナーゼ阻害剤 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014230111A1 (en) * | 2013-03-15 | 2015-10-29 | Oncodesign S.A | Macrocyclic RIP2 kinase inhibitors |
| AU2015292818B2 (en) | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| CA3069016A1 (en) | 2016-07-05 | 2018-01-11 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| AU2018226771B2 (en) | 2017-02-28 | 2023-11-23 | Dana-Farber Cancer Institute, Inc. | Uses of pyrimidopyrimidinones as SIK inhibitors |
| EP3391907B8 (en) | 2017-04-20 | 2020-03-04 | iOmx Therapeutics AG | Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof |
| WO2019120267A1 (zh) * | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| WO2020027200A1 (ja) | 2018-08-01 | 2020-02-06 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
| US11690897B2 (en) | 2019-02-04 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Salt inducible kinase inhibitors for enhancing fertility |
| CN117659043A (zh) * | 2022-09-07 | 2024-03-08 | 苏州朗睿生物医药有限公司 | 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| JP2010503690A (ja) * | 2006-09-18 | 2010-02-04 | ポラリス・グループ | タンパク質キナーゼ阻害剤として有用なピラゾロ（１，５−ａ）（１，３，５）トリアジン及びピラゾロ（１，５−ａ）ピリミジン誘導体 |
| JP2010509242A (ja) * | 2006-11-06 | 2010-03-25 | スーパージェン， インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 |
| JP2011520887A (ja) * | 2008-05-13 | 2011-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物 |
| JP2014528405A (ja) * | 2011-09-30 | 2014-10-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | マクロ環状ｌｒｒｋ２キナーゼ阻害剤 |
| JP2014528398A (ja) * | 2011-09-30 | 2014-10-27 | オンコデザイン エス．ア． | 大環状ｆｌｔ３キナーゼ阻害剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| SG48049A1 (en) | 1993-10-01 | 1998-04-17 | Astra Ab | Process i |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
-
2014
- 2014-03-14 KR KR1020157029486A patent/KR20150133767A/ko not_active Withdrawn
- 2014-03-14 BR BR112015022650A patent/BR112015022650A8/pt not_active IP Right Cessation
- 2014-03-14 HK HK16107168.3A patent/HK1219057A1/zh unknown
- 2014-03-14 AU AU2014230125A patent/AU2014230125A1/en not_active Abandoned
- 2014-03-14 CN CN201480023832.3A patent/CN105209040A/zh active Pending
- 2014-03-14 US US14/776,798 patent/US9586975B2/en not_active Expired - Fee Related
- 2014-03-14 EA EA201591794A patent/EA201591794A1/ru unknown
- 2014-03-14 SG SG11201507493SA patent/SG11201507493SA/en unknown
- 2014-03-14 CA CA2906262A patent/CA2906262A1/en not_active Abandoned
- 2014-03-14 WO PCT/EP2014/055168 patent/WO2014140313A1/en not_active Ceased
- 2014-03-14 MX MX2015012528A patent/MX2015012528A/es unknown
- 2014-03-14 JP JP2015562215A patent/JP2016510797A/ja not_active Ceased
-
2015
- 2015-09-08 IL IL241325A patent/IL241325A0/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010503690A (ja) * | 2006-09-18 | 2010-02-04 | ポラリス・グループ | タンパク質キナーゼ阻害剤として有用なピラゾロ（１，５−ａ）（１，３，５）トリアジン及びピラゾロ（１，５−ａ）ピリミジン誘導体 |
| JP2010509242A (ja) * | 2006-11-06 | 2010-03-25 | スーパージェン， インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 |
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| JP2011520887A (ja) * | 2008-05-13 | 2011-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物 |
| JP2014528405A (ja) * | 2011-09-30 | 2014-10-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | マクロ環状ｌｒｒｋ２キナーゼ阻害剤 |
| JP2014528398A (ja) * | 2011-09-30 | 2014-10-27 | オンコデザイン エス．ア． | 大環状ｆｌｔ３キナーゼ阻害剤 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023516551A (ja) * | 2020-01-31 | 2023-04-20 | オンコデザイン エス．ア． | 大環状ｒｉｐ２－キナーゼ阻害剤 |
| JP7713461B2 (ja) | 2020-01-31 | 2025-07-25 | オンコデザイン プリシジャン メディシン（オーピーエム） | 大環状ｒｉｐ２－キナーゼ阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2906262A1 (en) | 2014-09-18 |
| SG11201507493SA (en) | 2015-10-29 |
| US20160024113A1 (en) | 2016-01-28 |
| EA201591794A1 (ru) | 2015-12-30 |
| AU2014230125A1 (en) | 2015-10-29 |
| CN105209040A (zh) | 2015-12-30 |
| US9586975B2 (en) | 2017-03-07 |
| MX2015012528A (es) | 2016-04-15 |
| BR112015022650A2 (pt) | 2017-07-18 |
| IL241325A0 (en) | 2015-11-30 |
| BR112015022650A8 (pt) | 2018-01-23 |
| HK1219057A1 (zh) | 2017-03-24 |
| WO2014140313A1 (en) | 2014-09-18 |
| KR20150133767A (ko) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510797A (ja) | 大環状塩誘導性キナーゼ阻害剤 | |
| JP6082397B2 (ja) | マクロ環状ｌｒｒｋ２キナーゼ阻害剤 | |
| JP6046728B2 (ja) | 大環状ｆｌｔ３キナーゼ阻害剤 | |
| CA2853256C (en) | Novel purine derivatives and their use in the treatment of disease | |
| KR20200036922A (ko) | 단백질 아르기닌 메틸트랜스퍼라제 5 (prmt5)의 선택적 억제제 | |
| JP2016510796A (ja) | 大環状ｒｉｐ２キナーゼ阻害剤 | |
| EP3194405B1 (en) | Macrocyclic lrrk2 kinase inhibitors | |
| JP2016510793A (ja) | 大環状ｌｒｒｋ２キナーゼ阻害剤 | |
| RS65761B1 (sr) | Analozi rapamicina i njihova upotreba | |
| JP6736545B2 (ja) | 大環状ｒｉｐ２キナーゼ阻害剤 | |
| EP2968326A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| HK1232862A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| EP2968325A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| HK1232862B (zh) | 大环rip2激酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170217 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20171019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171020 |
|
| AA92 | Notification that decision to refuse application was cancelled |
Free format text: JAPANESE INTERMEDIATE CODE: A971092 Effective date: 20171205 |